NCT06676293View on ClinicalTrials.gov

Compassionate Use of Asparaginase and Pembrolizumab Combination Theaapy for Nasopharyngeal Carcinoma

NACompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

April 30, 2024

Study Completion Date

August 1, 2024

Conditions
Nasopharyngeal Carcinoma (NPC)
Interventions
DRUG

Anti-PD1

Pembrolizumab 100mg in normal saline 100ml infusion over 30 minutes for every two month

DRUG

asparaginase

The patients will receive asparaginase 10000IU/vail IM QD for three or five days.

Trial Locations (1)

333

Chang Gung Memorial Hospital, Taoyuan

All Listed Sponsors
lead

Chang Gung Memorial Hospital

OTHER